Seattle Genetics to acquire Cascadian Therapeutics for $614m to bolster oncology portfolio

Seattle Genetics, a leader in oncology biotechnology, has announced the acquisition of Cascadian Therapeutics for approximately $614 million, a strategic move to enhance its portfolio ... Read More